FULC FY 2023 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-55.8% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$111M-3945.2% margin

Net Income

-$97M-3470.1% margin

EPS (Diluted)

$-1.59

Cash Flow

Operating Cash Flow

-$91M

Free Cash Flow

-$91M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$258M

Total Liabilities

$23M

Stockholders' Equity

$235M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$6M	-55.8%
Gross Profit	$3M	-$70M	+104.0%
Operating Income	-$111M	-$113M	+1.7%
Net Income	-$97M	-$110M	+11.4%